CD8A and neoplasm: From a clinical standpoint, a recent study provided encouraging data demonstrating that the NOX4 inhibitor GKT137831 (Setanaxib) was capable of overcoming immunotherapy resistant tumor growth by suppressing the exclusion of CD8+ T-cells from the tumor cells’ environment in in vivo rodent models [227].